PARP1 is altered in 1.47% of malignant solid tumor patients [3].

PARP1 is an inclusion criterion in 14 clinical trials for malignant solid tumor, of which 12 are open and 2 are closed. Of the trials that contain PARP1 status and malignant solid tumor as inclusion criteria, 7 are phase 1 (7 open), 4 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [4].

PARP1 is altered in 0.92% of prostate adenocarcinoma patients [3].

PARP1 is an inclusion criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain PARP1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [4].

PARP1 is altered in 0.95% of prostate carcinoma patients [3].

PARP1 is an inclusion criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain PARP1 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [4].

PARP1 is altered in 1.88% of breast carcinoma patients [3].

PARP1 is an inclusion criterion in 5 clinical trials for breast carcinoma, of which 4 are open and 1 is closed. Of the trials that contain PARP1 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 2 (1 open) [4].

PARP1 is altered in 1.05% of ovarian carcinoma patients [3].

PARP1 is an inclusion criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PARP1 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [4].

PARP1 is altered in 1.92% of colorectal carcinoma patients [3].

PARP1 is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PARP1 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [4].

PARP1 is altered in 0.75% of cervical carcinoma patients [3].

PARP1 is an inclusion criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PARP1 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].

PARP1 is an inclusion criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PARP1 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [4].

PARP1 is altered in 3.4% of endometrial carcinoma patients [3].

PARP1 is an inclusion criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PARP1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

PARP1 is altered in 1.19% of non-small cell lung carcinoma patients [3].

PARP1 is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PARP1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].

PARP1 is altered in 0.55% of adenocarcinoma of the gastroesophageal junction patients [3].

PARP1 is an inclusion criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain PARP1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

PARP1 is altered in 0.72% of non-hodgkin lymphoma patients [3].

PARP1 is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain PARP1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].

PARP1 is altered in 0.43% of head and neck squamous cell carcinoma patients [3].

PARP1 is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PARP1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [4].

PARP1 is an inclusion criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PARP1 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [4].

PARP1 is altered in 9.09% of penile carcinoma patients [3].

PARP1 is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PARP1 status and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

PARP1 is altered in 3.03% of melanoma patients [3].

PARP1 is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PARP1 is altered in 2.91% of small cell lung carcinoma patients [3].

PARP1 is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PARP1 is altered in 2.12% of bladder urothelial carcinoma patients [3].

PARP1 is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PARP1 is altered in 1.8% of urothelial carcinoma patients [3].

PARP1 is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PARP1 is altered in 1.9% of malignant intestinal neoplasm patients [3].

PARP1 is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PARP1 is altered in 1.43% of malignant small intestinal neoplasm patients [3].

PARP1 is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PARP1 is altered in 1.6% of gastric carcinoma patients [3].

PARP1 is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PARP1 is altered in 1.6% of malignant gastric neoplasm patients [3].

PARP1 is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PARP1 is altered in 1.23% of esophageal carcinoma patients [3].

PARP1 is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PARP1 is altered in 1.21% of malignant esophagogastric neoplasm patients [3].

PARP1 is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PARP1 is altered in 1.13% of malignant ovarian epithelial tumor patients [3].

PARP1 is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PARP1 is altered in 1.12% of high grade ovarian serous adenocarcinoma patients [3].

PARP1 is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains PARP1 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

PARP1 is altered in 1.33% of diffuse large B-cell lymphoma patients [3].

PARP1 is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PARP1 is altered in 2.25% of anal carcinoma patients [3].

PARP1 is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PARP1 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

PARP1 is altered in 1.1% of cholangiocarcinoma patients [3].

PARP1 is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PARP1 is altered in 0.63% of mantle cell lymphoma patients [3].

PARP1 is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PARP1 is altered in 0.65% of pancreatic adenocarcinoma patients [3].

PARP1 is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PARP1 is altered in 0.64% of pancreatic carcinoma patients [3].

PARP1 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PARP1 is altered in 0.45% of mature T-cell and NK-cell non-hodgkin lymphoma patients [3].

PARP1 is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PARP1 is altered in 0.74% of soft tissue sarcoma patients [3].

PARP1 is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains PARP1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

PARP1 is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PARP1 is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PARP1 is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PARP1 status and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

PARP1 is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PARP1 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].